Lercanidipine Accord

Lercanidipine, the active ingredient in Lercanidipine Accord, is a calcium channel blocker presented as an oral tablet for oral administration. It selectively relaxes vascular smooth muscle, leading to vasodilation and a reduction in systemic blood pressure, and is indicated for the treatment of hypertension in adult patients.

GNH USA supplies Lercanidipine Accord as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide. The company ensures regulatory compliance and reliable logistics for global markets, supporting timely delivery and traceability.

Lercanidipine is a calcium channel blocker used to manage hypertension, a condition characterized by elevated arterial pressure. - Hypertension: lowers elevated blood pressure and helps maintain target blood pressure levels in adult patients.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate headache, often transient. - Flushing: sensation of warmth and redness, especially on the face. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: light‑headedness, particularly after standing. - Tachycardia: increased heart rate. - Palpitations: awareness of heart beating.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Angioedema: rapid swelling of face, lips, tongue, or throat. - Myocardial infarction: rare occurrence of heart attack. - Hepatic enzyme elevation: abnormal liver function tests. - Severe allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, certain precautions should be considered. - Blood pressure monitoring: regularly assess blood pressure to ensure therapeutic effect. - Hepatic impairment: use with caution in patients with liver dysfunction. - Elderly patients: start at lower doses and monitor for hypotension. - Concomitant antihypertensives: avoid excessive blood pressure lowering when combined with other agents. - CYP3A4 inhibitors: avoid strong inhibitors that may increase drug exposure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise plasma levels and increase risk of hypotension. - Grapefruit juice: can markedly increase drug exposure. - Concurrent use with other potent vasodilators: may cause excessive blood pressure drop.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: may enhance antihypertensive effect, requiring dose adjustment. - Beta‑blockers: additive effect on heart rate and blood pressure. - NSAIDs: may attenuate antihypertensive response.